Program Co-leader: Transplant Biology and Therapy Research Program
Professor, Department of Medicine
Director, Adult Blood and Marrow Transplant Program

weisd001@umn.edu
612-624-3101 — office
Preferred method of contact: e-mail

Dr. Weisdorf's clinical profile
(University of Minnesota Physicians Web site)

Dr. Weisdorf received his M.D. from the Chicago Medical School and completed an internal medicine residency at Michael Reese Hospital in Chicago. He completed a Hematology Oncology fellowship at the University of Minnesota. He now serves as director of the Adult Blood and Marrow Transplant Program at the University of Minnesota; co-leader of the Transplant Biology and Therapy Research Program; scientific director of the National Marrow Donor Program; and senior research advisor for the Center for International Blood and Marrow Transplant Research.

Research Interests

• Applications, complications and long term outcomes of hematopoietic stem cell transplantation.
• Prevention and management of graft vs. host disease immunotherapy of malignancies

Selected Publications

Giralt S, Logan B, Rizzo D, Zhang MJ, Ballen K, Emmanouilides C, Nath R, Parker P, Porter D, Sandmaier B, Waller EK, Barker J, Pavletic S, Weisdorf D: Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: Long-term follow-up of the first 258 reported to the National Marrow Donor Program. Biol Blood Marrow Transplant, 13(7)844-852, 2007.

Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Wagner JE, Arora M, Kaufman DS, Burns LJ, Miller JS, Slungaard A, McGlave PB, Weisdorf DJ: Reduced intensity allogeneic transplant in patients older than 55 years: Unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant, 14:282-289, 2008.

Tomblyn M, Brunstein C, Burns LJ, Miller JS, MacMillan M, DeFor TE, Weisdorf DJ: Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 14:538-545, 2008.

Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C, Setterholm M, Drexler R, Maiers M, King R, Confer D, Klein J: Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant, 14:748-758, 2008.

Marks DI, Perez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ: Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood, 112:426-434, 2008.

Majhail NS, Brunstein CG, McAvoy S, Defor TE, Al-Hazzouri A, Setubal D, Arora M, Le CT, Wagner JE, Weisdorf DJ: Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant, 14:985-992, 2008.

Dehn J, Arora M, Spellman S, Setterholm M, Horowitz M, Confer D, Weisdorf D: Unrelated donor hematopoietic cell transplantation: factors associated with a better HLA match. Biol Blood Marrow Transplant, 14:1334-1340, 2008.

Warlick ED, Cioc A, DeFor T, Dolan M, Weisdorf D: Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant, 15:30-38, 2009.

Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le C, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ: Donors with Group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood, 113:726-732, 2009.

Bachanova V, Brunstein CG, Burns LJ, Miller JS, Luo X, Defor T, Young JA, Weisdorf DJ, Tomblyn M: Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant, 43:237-244, 2009.

Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ: Costs of hematopoietic-cell transplantation: Comparison of umbilical cord blood and matched related donor transplantation and the impact of post-transplant complications. Biol Blood Marrow Transplant. 2009 May;15(5):564-73. Epub 2009 Mar 9

Arora M, Weisdorf DJ, Spellman S, Haagenson M, Klein P, Hurley CK, Selby GB, Antin JH, Kernan NA, Kollmann C, Nademanee A, McGlave P, Horowitz MM, Petersdorf E: HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol. 2009 Apr 1;27(10):1644-52. Epub 2009 Feb 17

Tomblyn MB, Arora A, Baker KS, Blazar BR, Brunstein CG, Burns LJ, DeFor TE, Dusenbery KE, Kaufman DS, Kersey JH, MacMillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ: Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol, 2009. (In Press)

Bachanova V, Verneris MR, Defor T, Brunstein C, Weisdorf D: Prolonged survival in adults with acute lymphoblastic leukemia (ALL) following reduced intensity conditioning with cord blood or sibling donor transplantation. Blood, 2009. (In Press)